Dendritic cell (DC)-based cancer immunotherapy is a promising method, but so far has demonstrated limited clinical benefits. Regulatory T cells (Tregs) represent a major obstacle to cancer immunotherapy approaches. Here we show that inhibiting p38 MAPK during DC differentiation enables DCs to activate tumour-specific effector T cells (Teff), inhibiting the conversion of Treg and compromising Treg inhibitory effects on Teff. Inhibition of p38 MAPK in DCs lowers expression of PPARγ, activating p50 and upregulating OX40L expression in DCs. OX40L/OX40 interactions between DCs and Teff and/or Treg are critical for priming effective and therapeutic antitumour responses. Similarly, p38 MAPK inhibition also augments the T-cell stimulatory capacity of human monocyte-derived DCs in the presence of Treg. These findings contribute to ongoing efforts to improve DC-based immunotherapy in human cancers.
Dendritic cell (DC)-based immunotherapy holds great promise for treating malignancies1. However, the results of most DC-based clinical trials have been disappointing2. In cancer patients, CD4+CD25+Foxp3+ regulatory T cells (Tregs) accumulate in tumours and secondary lymphoid organs by the mechanisms of expansion of Treg or the conversion of effector T cells (Teff)3,4. Tumour-associated Tregs likely contribute to the suppressive milieu, leading to the suppression of T-cell responses partly via the inhibition of DC functions5. Thus, modulating the suppressive function of Treg is essential for induction of effective antitumour immunity6,7.
Among the possible strategies to target Treg in vivo, depletion of CD25+ T cells by anti-CD25 antibodies may not be a viable approach because both Treg and activated Teff are depleted, inducing conversion of peripheral precursors into Treg4,8,9,10. A unique surface marker for Treg has not been identified, and an alternative approach to target Treg is the use of cytotoxic T lymphocyte antigen 4 (CTLA4)-blocking antibodies or glucocorticoid-induced tumour necrosis factor receptor (GITR) receptor agonist antibodies to revert Treg-mediated suppression8,11. However, these strategies can result in over-activating of nonspecific T-cell immunity and have been linked to severe autoimmunity in multiple organs, thus limiting their further clinical applications12,13. Therefore, a more desirable approach is needed to modulate the suppressive function of Treg and activate Teff in an antigen-specific manner.
In an earlier study, we demonstrated that lipopolysaccharide (LPS)-induced activation of p38 mitogen-activated protein kinase (MAPK) has a detrimental effect on the generation of immature DCs (iDCs) in vitro14. We and others have also shown that tumour-derived suppressive factors inhibit the differentiation and function of DCs by upregulating p38 MAPK activity in DC precursors in both murine tumour models and cancer patients15,16,17,18. These abnormalities in the phenotype and T-cell stimulatory capacity of DCs could be restored by inhibiting p38 MAPK activity in progenitor cells15,16,17,18. Based on these observations, we hypothesized that p38 MAPK may attenuate antigen presentation and have an essential role in maintenance of self-tolerance in DC.
In this study, we inhibited p38 MAPK activity in DC precursors using the inhibitor SB202190, and inhibitor SB203580 and/or p38α-specific small intefering RNA (siRNA) transfection for confirmation. The inhibition of p38 MAPK results in sharply decreased PPARγ expression in DCs, which reduces functional inhibition of p50 transcriptional activities by PPARγ. In turn, p50 activation upregulates surface expression of OX40L on DCs, increasing their immunostimulatory potency, activating antigen-specific Teff, inhibiting Treg conversion and function, and facilitating tumour rejection.
p38 MAPK-inhibited DCs activate Teff in the presence of Treg
Among the four different p38 isoenzymes, p38α was the only p38 MAPK isoenzyme detected in the isolated bone marrow (BM) cells and generated iDCs and mature DCs (mDCs) from wild-type C57BL/6 mice (WT-B6 mice) (Supplementary Fig. 1a). We chose to use SB202190 and SB203580, two specific inhibitors of the α- and β-isoforms of p38 MAPK19. Treatment with 1.5 μM SB202190 or SB203580, but not the inactive analogue SB202474 (ref. 20), was sufficient to inhibit the p38 MAPK activity in BM cells, as determined by our previous studies16, and by the blockage of the phosphorylation of its downstream kinase MAPKAPK-2 (Supplementary Fig. 1b). To examine the role of p38 MAPK in regulating DC generation and maturation (all generated from BM cells from WT-B6 mice unless indicated specifically), flow cytometry was used to analyse the surface expression of various molecules related to antigen presentation. SB202190- and SB203580-treated, but not SB202474-treated, iDCs expressed higher levels of DC-related molecules compared with control iDCs (Supplementary Fig. 1c). After maturation, SB202190-treated mDCs (mSBDCs) and SB203580-treated mDCs (mSB80DCs) showed significantly higher levels of major histocompatibility complex (MHC) class II, CD80, CD86, CD40 and OX40L than dimethylsulphoxide (DMSO)-treated control mDCs and SB202474-treated mDCs (mSB74DCs) (Fig. 1a,b and Supplementary Fig. 1d). In addition, p38 MAPK inhibition enhanced interleukin (IL)-12 production by mSBDCs and mSB80DCs (Supplementary Fig. 1e). All these cells produced undetectable or very low levels of cytokines such as IL-6, TNF-α, IL-10 and interferon (IFN)-γ (ranging from 0 to 50 pg ml−1). In line with these results, knockdown of p38α in DC progenitor cells by p38α-specific siRNA during the differentiation also induced the upregulated expression of DC-related surface molecules as compared with nonspecific siRNA-treated (Si-non-) mDCs (Supplementary Fig. 2). Collectively, these results suggested that p38 MAPK negatively regulated the generation and immunogenicity of BM-derived DCs (BMDCs).
The enhanced immunogenicity of mSBDCs and mSB80DCs may enable them to promote proliferation of activate Teff in the presence of Treg. We used a carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution assay to test the proliferation of Teff. As shown in Fig. 1c and Supplementary Fig. 3, mSBDCs, mSB80DCs or p38α-specific siRNA-treated (Si-p38α-) mDCs induced a profound proliferation of CD4+ Teff in the presence of Treg, whereas the proliferation of CD4+ Teff stimulated by mDCs, mSB74DCs or Si-non-mDCs was largely inhibited. Notably, the proliferation of CD4+ Teff stimulated by mSBDCs or mSB80DCs in the presence of Treg was even stronger than those stimulated by mDCs in the absence of Treg. We found that CD4+ Teff proliferation induced by mSBDCs, mSB80DCs or Si-p38α-mDCs was inhibited significantly by Treg when OX40L-blocking monoclonal antibody (mAb) was added (Fig. 1d and Supplementary Fig. 3). We also screened other molecules that might have contributed to this effect by using functional grade blocking mAbs targeting CD80, CD86, CD40 or IL-12 (Supplementary Fig. 1f–h), and excluded their involvement (Fig. 1d). These data suggest that the enhanced stimulatory function of mSBDCs and mSB80DCs is mediated exclusively by upregulated OX40L expression.
Flow cytometry analysis showed that mSBDCs expressed significantly higher levels of surface OX40L, and Teff stimulated by mSBDCs expressed significantly upregulated OX40L than T cells stimulated by mDCs (Supplementary Fig. 4a,b). As Tregs do not express OX40L22, we next examined the contribution of cell expression of OX40L. We used OX40L-specific siRNA-treated mSBDCs (Si-OX40L–mSBDCs; Supplementary Fig. 4b), and found that CD4+ Teff proliferation induced by Si-OX40L–mSBDCs was subject to Treg-mediated suppression (Fig. 1e). This Si-OX40L–mSBDC-induced Teff proliferation decreased further to the level of mDC-induced CD4+ Teff proliferation in the presence of Treg when OX40L-blocking antibody was added (Supplementary Fig. 4c), indicating that mSBDC-expressed OX40L had a major role in counteracting Treg-mediated suppression of Teff proliferation, and that Teff-expressed OX40L may also be important. These results suggested that mSBDCs may be able to induce tumour-specific T-cell responses even in the presence of Treg.
OX40 costimulation inhibits Treg and activates Teff
In the absence of Treg, the OX40/OX40L signalling appears to only have a minimal effect on proliferation of CD4+ Teff (Fig. 2a and Supplementary Fig. 3). As Tregs constitutively express OX40 and activated Teff but not DCs express OX40 (refs 21, 23, 24, 25), we next determined the contribution of cell expression of OX40 for the activation of Teff by mSBDCs in the presence of Treg. We first examined the role of OX40 expression on Teff. As shown in Fig. 2b, there was only a marginal decrease in the proliferation of OX40−/− CD4+ Teff, as compared with WT Teff, in response to mSBDCs or mDCs. However, when Tregs were present, the proliferation of the OX40−/− CD4+ Teff stimulated by mSBDCs decreased significantly as compared with those of WT Teff, indicating that loss of OX40 on CD4+ Teff rendered them more sensitive to Treg-mediated suppression as compared with their WT counterparts when stimulated by mSBDCs. In addition, we also investigated the role of Treg-expressed OX40 in Treg-mediated suppressive function. Since OX40−/− Treg from OX40−/− mice showed impaired suppressive function24, we could not use OX40−/− Treg in our studies. We cocultured mSBDCs, OX40−/− CD4+ Teff and Treg, in which OX40/OX40L costimulation only occurs between mSBDCs and Treg, and found that the proliferation of OX40−/− CD4+ Teff induced by mSBDCs was significantly inhibited when OX40L-blocking antibody was added (Fig. 2c), suggesting that interaction between mSBDCs and Treg via OX40/OX40L costimulation may lead to reduced inhibitory ability of Treg. Furthermore, mSBDC-pretreated Treg became less effective in inhibiting the proliferation of OT-II Teff compared with control or mDC-pretreated Treg in an OX40L-dependent manner (Fig. 2d). Similar results were also obtained from CD8+ T cells stimulated by mSBDCs in the presence or absence of Treg (Supplementary Fig. 5). Thus, these findings indicate the importance of OX40/OX40L signalling in mSBDC-induced resistance to Treg inhibition of Teff proliferation.
OX40 costimulation by mSBDCs inhibits Teff conversion to Treg
We found a significantly smaller Treg population (CD4+CD25+Foxp3+) among CD4+ T cells in the lymph nodes of mSBDC-immunized mice as compared with mDC-immunized mice (Fig. 3a), indicating that mSBDCs inhibited the expansion of preexisting Treg and/or conversion of CD4+CD25− Teff to Treg. Since mSBDCs and mDCs had similar stimulatory effects on expansion of Treg (Supplementary Fig. 6a), we hypothesized that mSBDCs may inhibit the conversion of CD4+CD25− Teff to Treg. As shown in Fig. 3b, mSBDCs generated significantly fewer CD4+CD25+Foxp3+ Treg than mDCs in vitro cultures of CD4+CD25− Teff without exogenous TGF-β1. Surprisingly, when TGF-β1 induced a large number of Treg from Teff when stimulated with mDCs, mSB74DCs or Si-non-mDCs, mSBDCs, mSB80DCs and Si-p38α-mDCs strongly inhibited the conversion of Teff to Treg (Fig. 3b and Supplementary Fig. 6b,c).
To shed light on the mechanisms driving these effects, we screened IFN-γ, IL-4, IL-12, IL-6, OX40L and other molecules in mSBDCs for their potential contribution to the inhibition of Teff conversion to Treg7,26. Our results showed that mAbs blocking OX40L, but not other molecules (Supplementary Fig. 6d), almost completely abrogated the inhibitory effect of mSBDCs on Treg conversion (Fig. 3c), indicating that OX40/OX40L signalling may be involved. In addition, mSBDCs and mDCs had similar ability in conversion of OX40−/− Teff into Treg in the presence or absence of exogenous TGF-β1 (Fig. 3c). Moreover, in vivo blocking OX40/OX40L pathway by injecting OX40L-blocking antibodies restored the generation of Treg population in tumour-draining lymph nodes from mSBDC-immunized mice to the same level of mice immunized with mDCs (Supplementary Fig. 7). To elucidate the mechanism underlying mSBDC-inhibited conversion of Treg, we investigated the binding of phosphorylated (p)Smad3 to the enhancer region I of Foxp3 promoter, in light of a previous study showing that the binding of pSmad3 to the enhancer region I increases Foxp3 transcription, whereas the binding of pStat3 to the conserved enhancer region II works as a gene silencer during Foxp3 transcription (Fig. 3d)27. Our results show that, although the level of pSmad3 and pStat3 did not change in CD4+ T cells cocultured with mDCs or mSBDCs in the presence of TGF-β1 (Supplementary Fig. 6e), binding of pSmad3 to the enhancer region I and pStat3 to the enhancer region II were significantly suppressed or enhanced, respectively, in mSBDC-cocultured CD4+ T cells in an OX40L-dependent manner (Fig. 3e,f). These results suggest epigenetic inhibition of Treg generation by mSBDCs. Together, these findings show that OX40/OX40L signalling provided by mSBDCs may contribute to the reduced generation of immunosuppressive cells in vitro and in vivo.
Sustained p50 activation mediates OX40L expression in mSBDCs
Our results indicate that both enhanced stimulatory function of mSBDCs and the inhibition of Teff conversion into Treg by mSBDCs are mediated exclusively by OX40L. We next elucidated the molecular mechanism underlying p38 inhibition-mediated upregulation of OX40L in mSBDCs. Because nuclear factor-κB (NF-κB) pathway contributes to the immunogenicity of DCs and Ox40l promoter contains a potential NF-κB binding site (5′-GGGAAATTCA-3′,−84 to −75, upstream of Ox40l), we hypothesized that the NF-κB pathway has an important role in the increased expression of OX40L on mSBDCs. By comparing NF-κB molecules in the nuclear fractions of mDCs and mSBDCs, we found that inhibition of p38 MAPK resulted in slightly increased nuclear translocation of RelA and RelB and robust nuclear translocation of p50 (Fig. 4a and Supplementary Fig. 8). Similarly, as compared with untreated mDCs and Si-non-mDCs, Si-p38α-mDCs also demonstrated a substantially upregulated nuclear translocation of p50 (Supplementary Fig. 9a). Next, by chromatin immunoprecipitation (ChIP) assay, we detected an increased physiological binding of RelA, RelB and especially p50 to the Ox40l promoter in mSBDCs (Fig. 4b). To examine whether these NF-κB molecules could activate the Ox40l promoter, we performed luciferase reporter gene assays in HEK 293T cells. RelA, RelB or p52 alone did not activate the Ox40l promoter, whereas p50 together with RelB, and to a lesser extent, with RelA or c-Rel, did (Fig. 4c). Considering that these NF-κB molecules were increased in the nuclear fraction of mSBDCs, these data indicate that nuclear translocation of p50, which formed transcriptionally active complexes with RelA, c-Rel and especially with RelB, was responsible for the upregulation of OX40L expression in mSBDCs.
To further verify the p50-dependent upregulation of surface expression of OX40L on mSBDCs, we generated BMDCs from BM cells of p50−/−B6-mice. The expression of OX40L on p50−/− iDCs and p50−/− mDCs was significantly reduced as compared with those generated from BM cells of WT-B6 mice (Fig. 4d,e). Furthermore, SB202190-treated p50−/− iDCs or p50−/− mDCs failed to upregulate the expression of surface OX40L. The surface OX40L expression level was similar between p50−/− mDCs and p50−/− mSBDCs, confirming a crucial role of p50 in modulating OX40L expression of mSBDCs.
Inhibition of PPARγ contributes to p50 activation in mSBDCs
Next, we examined the signalling pathways that may lead to activation of p50 following p38 inhibition. As IκB-α did not decrease in mSBDCs (Supplementary Fig. 9b), we performed gene array analysis to investigate the potential molecules that may have contributed to the nuclear translocation of p50. We hypothesized that the decreased PPARγ expression we observed in gene array analysis may have a role in activating p50 (ref. 22). First, we verified that the protein level of PPARγ was sharply decreased in mSBDCs as compared with mDCs (Fig. 5a and Supplementary Fig. 10) and in Si-p38α-mDCs as compared with Si-non-mDCs (Supplementary Fig. 9c). Also, the level of CCAAT/enhancer-binding protein (pC/EBPβ), a known downstream target of p38 MAPK28, was reduced in mSBDCs and in Si-p38α-mDCs (Fig. 5a and Supplementary Figs 9c and 10), which could potentially be responsible for decreased levels of PPARγ, considering it is the master transcriptional factor of PPARγ29. As a confirmation for the observations, knockdown of C/EBPβ by siRNA diminished PPARγ level in mDCs (Fig. 5b and Supplementary Fig. 10).
Second, we measured PPARγ activity by detection of mRNA levels of Ap2, which has been described as a direct PPARγ target30. As expected, inhibition of p38 MAPK reduced Ap2 levels in mDCs as well as the PPARγ inhibitor, whereas both rosiglitazone (RGZ), a PPARγ activator, and the p38 activator, anisomycin31, enhanced Ap2 expression (Fig. 5c). In addition, inhibition of p38 MAPK failed to suppress PPARγ activity directly induced by RGZ (Fig. 5c). By analysis of the nuclear translocation of p50, we found that p50 activity was retroactively correlated with PPARγ activity in mDCs (Fig. 5c,d and Supplementary Fig. 10). Moreover, we detected the presence of p50 in PPARγ immunoprecipitate from mDCs but not from mSBDCs (Fig. 5e and Supplementary Fig. 10), suggesting a possible mechanism of transrepression of p50 activity by PPARγ by complex formation22, which antagonizes p50 signalling in DCs.
Finally, we also found that PPARγ inhibitor-induced p50 activation led to upregulated expression of surface OX40L on mDCs, while p50 deficiency abrogated this effect (Fig. 5f,g). As inhibition of p38 MAPK could not reverse RGZ-mediated PPARγ activation, RGZ-treated mSBDCs failed to express the high levels of OX40L observed on mSBDCs (Fig. 5f,g). These results suggest that inhibition of p38 MAPK suppresses PPARγ expression and activity in mSBDCs by decreasing C/EBPβ phosphorylation, thereby leading to reduced functional inhibition of PPARγ on p50 transcription factor activity and increased expression of OX40L on mSBDCs.
mSBDCs overcome Treg-mediated immunosuppression in vivo
The observed regulatory role of p38 MAPK in DC differentiation and immunogenicity promoted us to examine whether p38 inhibited-mDC can induce potent antigen-specific antitumour immunity and facilitate tumour rejection. Similar to other reports of the B16-OVA32 and B16 (ref. 33) tumour model, mice were immunized with OT-I peptide-pulsed mSBDCs (mSBDCs-OT-I), mDCs-OT-I, mSBDCs-OT-II, mDCs-OT-II, mSBDC-TRP2 or mDC-TRP2 at days 3 and 10 after tumour cell inoculation. Groups of mice were depleted of CD25+ Treg with an intraperitoneal injection of CD25-specific antibody or treated with combined Treg cell depletion (3 days before immunization) and DC immunization. We (Supplementary Fig. 11a) and others34 have found that a single injection of CD25-specific antibody can deplete >90% of Treg for a week by examining CD25+Foxp3+ T cells in the spleens. Tumour growth was significantly inhibited by immunization with mSBDCs-OT-I, mSBDCs-OT-II or mSBDC-TRP2, whereas immunization with non-pulsed mSBDCs or Treg depletion had marginal effects, and mDCs-OT-I, mDCs-OT-II or mDC-TRP2 immunization had moderate antitumour effects (Fig. 6a–c and Supplementary Fig. 11b). Notably, mSBDCs immunization alone was at least as effective as the combined treatments of Treg depletion and mDC immunization in inhibiting the growth of pre-established tumour (Fig. 6a–c). In addition, the enhanced antitumour effects of antigen-pulsed mSBDCs were correlated with the significantly higher frequencies of antigen-specific CD4+ or CD8+ IFN-γ-secreting T cells in spleens and the significantly increased CTL activity in immunized mice (Fig. 6d–f and Supplementary Fig. 11c). Importantly, Si-p38α-mDCs-OT-I, mSBDCs-OT-I and mSB80DCs-OT-I, but not the Si-non-mDCs-OT-I, mDCs-OT-I and mSB74DCs-OT-I, could prevent the outgrowth of pre-established B16-OVA tumour (Supplementary Fig. 11d–g), further demonstrating the crucial role of inhibiting p38 MAPK signalling in DCs to induce superior antitumour response after immunization.
We also examined the contribution of OX40L signal delivered by mSBDCs in activating T-cell immunity. We found that OX40L antibody treatment could abrogate the proliferation of activated OT-II T cells induced by mSBDC-OT-II in tumour-draining lymph nodes (Supplementary Fig. 12), and substantially reduced the ability of mSBDCs-OT-II and mSBDCs-OT-I to induce tumour regression (Supplementary Fig. 13). Furthermore, p50−/− mSBDCs-OT-I expressed low levels of OX40L and failed to induce an effective antitumour response compared with mSBDCs-OT-I from WT mice (Supplementary Fig. 11f). These observations reveal the importance of OX40 costimulation initiated by mSBDCs in inducing antitumour immunity in vivo.
mSBDCs activate antitumour immunity in the effector phase
We then examined the in vivo effects of mSBDCs in the effector phase of antitumour immune response. Tumour-infiltrating lymphocytes (TILs) were isolated from B16-OVA tumour-bearing C57BL/6 mice receiving different treatments. The numbers of tumour-infiltrating, IFN-γ-secreting CD8+ or CD4+ T cells were significantly increased in mSBDCs-OT-I- or mSBDCs-OT-II-immunized mice, respectively, than the other groups (Fig. 7a). We observed a significantly upregulated expression of OX40 and OX40L on both CD8+ and CD4+ Teff that might amplify the OX40/OX40L signal on the effector phase of antitumour immune response (Fig. 7b). Tumour-infiltrating CD8+ or CD4+CD25− (Fig. 7c) Teff isolated from mice immunized with mSBDCs-OT-I or mSBDCs-OT-II, respectively, had significantly enhanced proliferation when restimulated in vitro with OT-I or OT-II peptide-loaded mDCs than those from other groups, even in the presence of CD4+CD25+ Treg from naive mice. We also analysed tumour-infiltrating CD4+CD25+Foxp3+ Treg population, and to our surprise, mSBDCs-OT-I or mSBDCs-OT-II immunization resulted in significantly decreased percentages of Treg in gated CD4+ TILs (Fig. 7d). Moreover, CD4+CD25hi Treg isolated from TILs in mSBDCs-OT-II-immunized mice had significantly decreased suppressive function as compared with those from mDC-immunized or phosphate buffered saline (PBS)-treated mice in inhibiting the proliferation of CD4+CD25− OT-II cells stimulated with mDCs-OVA (Fig. 7e). In addition, as compared with mSBDCs-OT-I, mSB74DCs-OT-I and p50−/− mSBDCs-OT-I displayed significantly decreased capacity to activate tumour-infiltrating Teff, reduce Treg cell population and compromise the suppressive function of tumour-infiltrating Treg (Supplementary Fig. 14). Taken together, these data indicate that the inhibited p38 MAPK signalling, as well as the subsequently activated p50 NF-κB pathway, are indispensable for mSBDC-stimulated activation of tumour-infiltrating Teff during the effector phase.
The role of p38 MAPK in human monocyte-derived DCs
We further asked whether p38 MAPK inhibition could enhance the Teff-stimulatory capacity of human monocyte-derived DCs (h-MoDCs) in the presence of Treg. Inhibition of p38 MAPK during the differentiation of h-MoDCs by 1 μM SB202190 or SB203580, but not SB202474 or DMSO, significantly upregulated the surface expression of OX40L on these cells after maturation (Fig. 8a). In the absence of Treg, the OX40/OX40L signalling appears to only have a minimal effect on the proliferation of alloreactive CD4+ Teff induced by p38 MAPK inhibitor-treated h-mMoDCs (Fig. 8b). Importantly, similar to murine p38 MAPK-inhibited BMDCs, p38 MAPK inhibitor-treated h-mMoDCs induced a profound proliferation of alloreactive CD4+ Teff in the presence of autologous Treg, whereas the proliferation of CD4+ Teff stimulated by SB202474- or DMSO-treated h-mMoDCs was largely inhibited (Fig. 8c). OX40 costimulation is crucial to p38 MAPK inhibitor-treated h-mMoDCs-mediated activation of Teff in the presence of Treg, because OX40L blockage abrogated this effect (Fig. 8c). Overall, these results highlight the translational potential of inhibition of p38 MAPK during the differentiation of h-MoDCs for improving DC-based immunotherapy in human cancers.
p38 MAPK activity is required for LPS-, TNF-α- and CD40L-induced maturation of iDCs35,36. However, the present study shows that p38 MAPK activity in DC progenitor cells acts as an antigen presentation attenuator, and disabling this critical brake during DC differentiation endows DCs with superior activity in antigen presentation and induction of immune responses. Our results further demonstrate the crucial role of inhibition of p38 MAPK activity in DCs in activating CD8+ and CD4+ T cells during both priming and effector phases of the immune response in an antigen-specific manner, possibly owing to the improved maturation status37 of mSBDCs as shown by the significantly enhanced expression of MHC class II, CD80, CD86, CD40 and OX40L, as well as IL-12 production. When p38 MAPK signalling in DC progenitor cells was inhibited, the remarkably improved maturation status of mSBDCs was not limited to maturation induced by TNF-α/IL-1β, but could also extend to other stimuli-induced maturation, such as LPS, Poly I:C, CpG, sCD40L and TNF-α/IL-1β/IL-6/prostaglandin E2 (PGE2; Supplementary Fig. 15). Additional inhibition of p38 MAPK during maturation had no obvious effect in improving SBDC maturation status when matured by TNF-α/IL-1β, sCD40L or TNF-α/IL-1β/IL-6/PGE2, but to some extent, suppressed the maturation of SBDCs stimulated by LPS, Poly I:C or CpG (Supplementary Fig. 15), indicating the important role of p38 MAPK in toll-like receptor (TLR) agonist-induced maturation of iSBDCs. Hence, this study provides new insights into an intracellular negative feedback mechanism, and indicates that DC generation and activation is self-limiting through p38 MAPK activation in DC progenitor cells.
We also found that the self-limiting regulation of DC immunogenicity, controlled by p38 MAPK, is mediated through transcriptional repression of NF-κB family members (Fig. 9). We showed that p38 MAPK phosphorylates C/EBPβ and pC/EBPβ induces the expression of PPARγ, whose activity affects the maturation and function of DCs38,39. PPARγ has been reported to physically associate with many distinct families of transcription factors, prevent the transcription factors from binding to their response elements and thus suppress their ability to induce gene transcription22. In line with this finding, our results revealed a physical interaction between PPARγ and NF-κB p50, which may repress the transactivation of p50. Inhibition of p38 MAPK in DCs abrogated this self-limiting regulation and resulted in a robust p50 nuclear translocation. This sustained activated p50 forms transcriptionally active complexes with RelA, c-Rel and especially with RelB, which bind the Ox40l promoter and induce the substantially increased expression of surface OX40L on mSBDCs. Our result that p50 deficiency abrogated the enhanced expression of OX40L on mSBDCs further supports this conclusion.
Tregs have a major role in tumour-related immune suppression, and have been considered as one of the most crucial hurdles to overcome for successful antitumour immunotherapy40. A recent report has shown an attenuated IL-10-secreting Treg induced by TLR agonists through inhibition of p38 MAPK signalling in DCs during maturation, owing to the decreased IL-10 production in DCs stimulated with TLR agonists41. In addition, others also showed that constitutive activation of p38 MAPK is responsible for inducing a tolerogenic profile in DCs during melanoma progression in tumour-bearing mice, with DCs secreting significantly more IL-10 and less IL-12 (ref. 42). Indeed, IL-12 might be downregulated by p38 MAPK signalling in many different antigen-presenting cells, especially following TLR agonists stimulation41,42,43,44,45. Our findings differ from these reports because we used cytokine cocktails, not TLR agonists, to mDCs; the former are more relevant to the cells that are being used in clinical trials. A surprising effect of mSBDCs in inhibiting conversion of Teff to CD4+CD25+Fop3+ Treg has been described in this study. The enhanced OX40/OX40L signals provided by mSBDCs may be responsible for the significantly decreased Treg cell population in the tumour and lymph nodes. In line with these result, several groups have reported that the generation of induced Treg is affected by OX40 costimulation25,46.
In addition to inhibition of Treg conversion, mSBDCs were more resistant to cancer- and Treg cell-derived suppressive factors (Supplementary Fig. 16). Notably, mSBDCs partially abrogated Treg-mediated immunosuppression by activating CD4+ or CD8+ Teff in the presence of Treg and by inhibiting the suppressive function of Treg, probably via the mechanism of enhanced OX40 signal on both Teff and Treg. Our results show that mSBDCs were as effective as combined treatments of mDC immunization and Treg depletion by anti-CD25 antibodies in controlling the growth of pre-established tumours. Importantly, we also evidenced profound effects of mSBDCs on the effector phase of antitumour immunity, as demonstrated by substantially increased antigen-specific, activated tumour-infiltrating CD4+ or CD8+ Teff that were more resistant to Treg-mediated suppression, and by the reduced suppressive function of tumour-infiltrating Treg that may be a result of the increased OX40 signalling delivered by mSBDCs and/or activated Teff within the tumours. OX40L expression is only observed on cells present at sites of inflammation and not in those invading tumours or on tumour cells themselves, and this insufficient ligation of OX40 could be a limiting factor for immune-mediated destruction of tumour cells47. In support of our findings, OX40L expressed by mDCs has been shown to be important for induction of antitumour immunity48, and other groups also demonstrated that OX40 signalling triggered by agonist antibodies facilitates tumour rejection by blocking the suppression of Treg49. Taken together, in addition to its strong immunostimulatory effects on Teff, mSBDCs can induce efficient antitumour immune responses by counteracting Treg-mediated immune suppression. Hence, mSBDCs should be very useful as a tool for DC-based immunotherapy to induce strong antitumour immune responses in cancer patients.
C57BL/6 mice were purchased from the National Cancer Institute (NCI), and OX40−/− (B6.129S4-Tnfrsf4tm1Nik/J), OT-II (C57BL/6-Tg(TcraTcrb)425Cbn/J),OT-I (C57BL/6-Tg(TcraTcrb)1100Mjb/J) and p50−/− (C57BL/6-129P-Nfkb1tm1Bal/J) mice were purchased from the Jackson Laboratory. Male, 6–8-week old mice were used in the beginning of each animal experiment. The studies were approved by the Institutional Animal Care and Use Committee of Cleveland Clinic Foundation.
Cell lines and reagents
The WT B16 and B16 transfected with OVA (B16-OVA) melanoma cell lines (American Type Culture Collection (ATCC)) were cultured in Iscove’s modified Dulbecco’s media (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo Scientific), 100 U ml−1 penicillin–streptomycin and 2 mM L-glutamine (both from Invitrogen). p38 MAPK inhibitor SB202190 and SB203580, and their inactive analogue SB202474 were purchased from EMD Biosciences. PGE2, p38 MAPK activator anisomycin, PPARγ activator RGZ and PPARγ inhibitor GW9662 were purchased from Sigma. MHC class II-restricted TRP1 (SGHNCGTCRPGWRGAACNQKILTVR), H2-Kb-restricted TRP2 (SVYDFFVWL), H2-Kb-restricted OT-I (SIINFEKL) and MHC class II-restricted OT-II (ISQAVHAAHAEINEAGR) peptides were purchased from GenScript. Murine OX40L-blocking antibody (RM134L), CD40-blocking antibody (16-0402), CD80-blocking antibody (16-10A1), CD86-blocking antibody (GL1), IL-12-blocking antibody (C17.8) and anti-CD25 antibody (PC6.1) were purchased from eBioscience. Human OX40L-blocking antibody (159403) was purchased from R&D Systems. Mouse or human Granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF-α, IL-1β, IL-4, IL-6, IL-2, sCD40L and human TNF-β1 were purchased from R&D Systems. LPS, CpG, Poly I:C were purchased from InvivoGen.
Mouse BMDCs were prepared as described previously50. In brief, BM cells were cultured with 2.5 ml of RPMI-1640 supplemented with 10% FBS and mGM-CSF (20 ng ml−1). At day 4, 2.5 ml fresh medium containing mGM-CSF (20 ng ml−1) was added. At day 7, semi-adherent cells were collected as iDCs. In some cultures, 1.5 μM of SB202190, SB203580 or SB202474 was added to the cultures on day 0, and cultures with addition of DMSO (0.1%; Sigma) served as control. iDCs collected at day 7 were extensively washed and maintained in medium containing mGM-CSF (10 ng ml−1) before adding TNF-α (10 ng ml−1) and IL-1β (10 ng ml−1) to help mature the cells. After 48 h, semi-adherent cells were collected as mDCs. No additional DMSO, SB202190, SB203580 or SB202474 was added during the culture or during maturation. Flow cytometry analysis showed that both iDCs and mDCs contain >90% of CD11c+ cells, while mDCs express significantly upregulated surface expression of DC-related molecules than iDCs (Supplementary Fig. 1).
h-MoDCs were generated as described previously51. Monocytes were positively selected from peripheral blood mononuclear cells of healthy donors using anti-CD14-conjugated magnetic microbeads (Miltenyi Biotec). Monocytes were cultured in AIM-V medium supplemented with 50 ng ml−1 human GM-CSF and human Interleukin 4 (hIL-4). In some cultures, 1 μM of SB202190, SB203580 (ref. 52) or SB202474 was added to the cultures on day 0. After 5 days, semi-adherent cells iDCs were extensively washed and then matured for 2 days by adding human tumor necrosis factor-α (hTNF-α) (10 ng ml−1), hIL-1β (10 ng ml−1), hIL-6 (10 ng ml−1) and 0.5 μg ml−1 PGE2. The study was approved by the Institutional Review Board Committee of Cleveland Clinic Foundation.
Flow cytometric analysis
Cells were stained with fluorescein isothiocyanate (FITC), phycoerythrin, (PE), allophycocyanin (APC)-conjugated mAbs (1:100 dilution) after pre-blocking FCγ receptors. Rat mAbs specific for mouse CD4 (GK1.5), CD8 (53-6.7), CD25 (PC6.1), CD11c (N418), CD40 (1C10), CD80 (16-10A1), CD86 (GL1), OX40L (RM134L), OX40 (OX86) and matched isotype controls were purchased from eBioscience. Intracellular IFN-γ staining for T cells was performed using a Cytofix/Cytoperm kit (BD Biosciences), with anti-IFN-γ (XMG1.2) antibodies (eBioscience). Before intracellular IFN-γ staining, splenocytes were restimulated by peptides (5 μg ml−1) or peptide-loaded mDCs at a 10:1 T cells to DCs ratio overnight, and for the final 6 h of culture, GolgiPlug (BD Biosciences–Pharmingen) was added. Foxp3 staining was performed using a Foxp3 staining kit (eBioscience) with anti-Foxp3 (FJK-16s) antibodies (eBioscience). For flow cytometric analysis, stained cells were analysed on a FACSCalibur (Becton Dickinson) and CELLQuest software.
In vivo CTL assay
In vivo CTL assay was performed as described previously53 with some modifications. Spleen cells from C57BL/6 mice were pulsed with 5 μg ml−1 OT-I peptide, OT-II peptide, TRP1 peptide or TRP2 peptide. Pulsed splenocytes were labelled with CFSE at a final concentration of 1 μM (CFSEhi) or at a final concentration of 0.1 μM (CFSElo). Two cell populations were mixed at 1:1 ratio, and 2 × 107 total cells were injected intravenously into treated mice. The percentage of antigen-specific lysis was determined 6 h later after target cell injection in OT-I peptide-loaded DC-immunized mice (OT-I peptide-pulsed CFSEhi target + TRP2 peptide-pulsed CFSElo non-target), 36 h later in TRP2 peptide-loaded DC-immunized mice (TRP2 peptide-pulsed CFSEhi target + OT-1 peptide-pulsed CFSElo non-target), and 36 h later in OT-II peptide-loaded DC-immunized mice (OT-II peptide-pulsed CFSEhi target + TRP1 peptide-pulsed CFSElo non-target), by analysing the relative proportion of CFSEhi target cells and CFSElo non-target cells in splenocytes based on CFSE-labeling intensity. The percentage of specific lysis was calculated as follows: (1−R × M2/M1) × 100, where M1 = non-target events, M2 = target events, R = M1 in untreated mice/M2 in untreated mice.
Isolation of TILs
On different days after DC immunization, mice were killed and TILs were isolated from tumour cell suspensions after a Ficoll gradient centrifugation to eliminate dead cells. Subsets of TILs (CD8+, CD4+CD25− and CD4+CD25+ T cells) were sorted with flow cytometer after staining.
Enzyme-linked immunosorbent assay and western blot
Enzyme-linked immunosorbent assay for IFN-γ and IL-12p70 production was performed by ELISA kits (R&D Systems). For western blot, anti-mouse p38α (cat. no. 9218), p38γ (cat. no. 2307), p38 (cat. no. 8690), p-p38 (cat. no. 4631), MAPKAPK-2 (cat. no. 3042), pMAPKAPK-2 (cat. no. 3041), RelA (cat. no. 4764), RelB (cat. no. 4954), p52 (cat. no. 4882), GAPDH (cat. no. 2118), PARP (cat. no. 9532), C/EBP-β (cat. no. 3087), pC/EBP-β (cat. no. 3084), PPARγ (cat. no. 2430), pStat3 (cat. no. 9145), Stat3 (cat. no. 12640), pSmad3 (cat. no. 9520), Smad3 (cat. no. 9523), IκB-α (cat. no. 4812) and β-actin (cat. no. 4970) from Cell Signaling (1:1,000 dilution), and anti-mouse p38β, (cat. no. sc-6187), p38δ, (cat. no. sc-7587), p50 (cat. no. sc-7178) and c-Rel (cat. no. sc-70) from Santa Cruz Biotechnology (1:250 dilution) were used.
T-cell proliferation and suppression assays
Splenic CD8+, CD4+CD25− or CD4+CD25+ T cells from WT, OX40−/−, OT-I- or OT-II-transgenic mice were isolated by using the MACS T-cell isolation kits (Miltenyi Biotec). T-cell proliferation was measured with CFSE dilution assay. CD8+ or CD4+CD25− T cells were incubated for 5 min at 37 °C with 1 μM CFSE in PBS and then washed extensively. For antigenic stimulation using TCR-transgenic OT-I or OT-II T cells and antigen-pulsed DCs, 1 × 105 purified T cells and 1 × 104 DCs pulsed with OT-I or OT-II peptides (1 μg ml−1) were seeded in each well of a round-bottom 96-well microtiter plate in triplicate in 200 ml RPMI-1640 medium supplemented with 10% FBS. For stimulation using WT or OX40−/− T cells, 1 × 105 purified T cells and 1 × 104 unpulsed DCs were cocultured in the presence of anti-CD3 antibodies (1 μg ml−1). For suppression assays, 1–2 × 105 unlabelled CD4+CD25+ Tregs were added in the cocultures. Isotype-matched control immunoglobulin G (IgG) and blocking mAbs were added at a concentration of 10 μg ml−1. We measured proliferation by relative CFSE dilution after 60 h of culture. For human T-cell proliferation, h-MoDCs were mixed with CFSE-labelled alloreactive CD4+CD25− Teff in Aim-V medium in the presence or absence of autologous CD4+CD25+ Treg. Human T-cell proliferation was assessed 6 days after coculture.
ChIP assay were performed with the ChIP assay kit (Millipore) according to the manufacturer’s instructions. Chromatin was extracted from CD4+Foxp3− T cells cocultured for 4 days with mDCs or mSBDCs in the presence of TGF-β1, mDCs and mSBDCs after fixation with formaldehyde. Anti-pSmad3, anti-pStat3, anti-RelA, anti-RelB, anti-p50 and isotype-matched control antibodies (all from Cell Signaling, 1:20 dilution) were used for the immunoprecipitation of chromatin. The precipitated DNA was analysed by reverse transcription (RT)–PCR with the following primer sets: surrounding region of NF-κB binding site at Ox40l promoter, 5′-CTTCAGAGCACACGTTTGTGAAT-3′ and 5′-TGAAGG AGCAGAGCAGAGTCTCTT-3′; enhancer I region: 5′-caggctgacctcaaactcacaaag-3′; 5′-catacccacacttttgacctctgc-3′; 5′-gcttctgtgtatggttttgtgt-3′; 5′-atcatcacagtacatacgagga-3′; enhancer II region: 5′-GGACGTCACCTACCACATCC-3′; 5′-CTACCCCACAGGTTTCGTTC-3′; 5′-AGAACTTGGGTTTTGCATGG-3′; 5′-TCTACCCCACAGGTTTCGTT-3′. Values were subtracted with the amount from IgG control and were normalized to corresponding input control.
Luciferase reporter assays
HEK 293T cells were transiently transfected with a 1121-bp mouse Ox40l promoter (Genecopoeia)-inserted luciferase reporter vector pEZX-PG04 (mOx40l-PG40), or control vector (NEG-PG40) and expression vectors for NF-κB molecules (p50, p52, RelA, RelB and c-Rel, Addgene) by Lipofectamine 2000 (Invitrogen). Promoter activity was measured with Secrete-Pair Dual Luminescence Assay Kit (GeneCopoeia) according to the manufacturer’s instructions. Values are expressed as the mean±s.d. of relative luciferase units normalized to internal control.
DC immunization and tumour models
iDCs, iSBDCs, p50−/− iSBDCs, iSB74DCs, iSB80DCs and siRNA-treated iDCs were pulsed with OT-I (5 μg ml−1), OT-II (15 μg ml−1) or TRP2 peptides (30 μg ml−1) for 8 h, and matured for additional 48 h in the presence of TNF-α and IL-1β. After washing with PBS, mDCs or treated mDCs were prepared for immunization of mice (five per group). In the therapeutic model, 3 × 105 B16-OVA or B16 tumour cells were injected subcutaneously into the right flank of WT C57BL/6 mice. Mice were then randomly divided into groups and injected with 1 × 106 mDCs or treated mDCs subcutaneously in the left back 3 and 10 days later. Tumour volumes were measured two or three times per week with an electronic caliper.
For statistical analysis, Student’s t-test was used. A P value <0.05 was considered statistically significant. In some Figures, the actual P values were shown as superscript numbers. Results are typically presented as means±s.d.
Accession codes: The microarray data were deposited in the NCBI Gene Expression Omnibus (GEO) database under accession numbers GSE57879.
How to cite this article: Lu, Y. et al. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat. Commun. 5:4229 doi: 10.1038/ncomms5229 (2014).
Gene Expression Omnibus
Kalinski, P., Muthuswamy, R. & Urban, J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev. Vaccines 12, 285–295 (2013).
Heiro, Y. i. D. & Appel, S. Current status and future perspectives of dendritic cell-based cancer immunotherapy. Scand. J. Immunol. 78, 167–171 (2013).
Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295–307 (2006).
Menetrier-Caux, C., Gobert, M. & Caux, C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res. 69, 7895–7898 (2009).
Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263–274 (2005).
Feng, L. L. & Wang, X. Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy. Chin. Med. J. (Engl) 123, 3334–3342 (2010).
Byrne, W. L., Mills, K. H., Lederer, J. A. & O'Sullivan, G. C. Targeting regulatory T cells in cancer. Cancer Res. 71, 6915–6920 (2011).
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y. & Sakaguchi, S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3, 135–142 (2002).
Piconese, S., Valzasina, B. & Colombo, M. P. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205, 825–839 (2008).
Valzasina, B., Piconese, S., Guiducci, C. & Colombo, M. P. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 66, 4488–4495 (2006).
Ramirez-Montagut, T. et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. 176, 6434–6442 (2006).
Cohen, A. D. et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 66, 4904–4912 (2006).
Attia, P. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043–6053 (2005).
Xie, J. et al. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J. Immunol. 171, 4792–4800 (2003).
Wang, S. et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 108, 4071–4077 (2006).
Wang, S. et al. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 107, 2432–2439 (2006).
Oosterhoff, D. et al. Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology 1, 649–658 (2012).
Cirone, M. et al. Dendritic cell differentiation blocked by primary effusion lymphoma-released factors is partially restored by inhibition of P38 MAPK. Int. J. Immunopathol. Pharmacol. 23, 1079–1086 (2010).
Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746 (1994).
Tabuchi, K. et al. Cochlear protection from acoustic injury by inhibitors of p38 mitogen-activated protein kinase and sequestosome 1 stress protein. Neuroscience 166, 665–670 (2010).
Croft, M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28, 57–78 (2010).
Takeda, I. et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J. Immunol. 172, 3580–3589 (2004).
Daynes, R. A. & Jones, D. C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2, 748–759 (2002).
Watts, T. H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23–68 (2005).
Jensen, S. M. et al. Signaling through OX40 enhances antitumor immunity. Semin. Oncol. 37, 524–532 (2010).
So, T. & Croft, M. Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J. Immunol. 179, 1427–1430 (2007).
Xu, L. et al. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity 33, 313–325 (2010).
Trempolec, N., Dave-Coll, N. & Nebreda, A. R. SnapShot: p38 MAPK signaling. Cell 152, 656–656e1 (2013).
Wu, Z., Bucher, N. L. & Farmer, S. R. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol. Cell. Biol. 16, 4128–4136 (1996).
Szatmari, I., Rajnavolgyi, E. & Nagy, L. PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function. Ann. NY Acad. Sci. 1088, 207–218 (2006).
He, J. et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 72, 6393–6402 (2012).
Song, X. T. et al. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med. 14, 258–265 (2008).
Evel-Kabler, K., Song, X. T., Aldrich, M., Huang, X. F. & Chen, S. Y. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 116, 90–100 (2006).
Prasad, S. J. et al. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J. Immunol. 174, 90–98 (2005).
Arrighi, J. F., Rebsamen, M., Rousset, F., Kindler, V. & Hauser, C. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J. Immunol. 166, 3837–3845 (2001).
Yu, Q., Kovacs, C., Yue, F. Y. & Ostrowski, M. A. The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses. J. Immunol. 172, 6047–6056 (2004).
Villadangos, J. A. & Schnorrer, P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 7, 543–555 (2007).
Szatmari, I. et al. PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 110, 3271–3280 (2007).
Kock, G. et al. Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone. Blood 117, 3569–3574 (2011).
Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715–727 (2006).
Jarnicki, A. G. et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J. Immunol. 180, 3797–3806 (2008).
Zhao, F. et al. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin. Cancer Res. 15, 4382–4390 (2009).
Yang, Z., Zhang, X., Darrah, P. A. & Mosser, D. M. The regulation of Th1 responses by the p38 MAPK. J. Immunol. 185, 6205–6213 (2010).
Franks, H. A. et al. Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10. Int. J. Cancer 134, 575–586 (2014).
Kuhnol, C., Herbarth, M., Foll, J., Staege, M. S. & Kramm, C. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunol. Immunother. 62, 1797–1809 (2013).
Vu, M. D. et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 110, 2501–2510 (2007).
Gough, M. J. & Weinberg, A. D. OX40 (CD134) and OX40L. Adv. Exp. Med. Biol. 647, 94–107 (2009).
Zaini, J. et al. OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J. Clin. Invest. 117, 3330–3338 (2007).
Moran, A. E., Kovacsovics-Bankowski, M. & Weinberg, A. D. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. 25, 230–237 (2013).
Hong, S. et al. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin. Exp. Immunol. 170, 167–177 (2012).
Legler, D. F., Krause, P., Scandella, E., Singer, E. & Groettrup, M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J. Immunol. 176, 966–973 (2006).
Xie, J. et al. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp. Hematol. 33, 564–572 (2005).
Keller, A. M., Schildknecht, A., Xiao, Y., van den Broek, M. & Borst, J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity 29, 934–946 (2008).
This work was supported by startup fund from Cleveland Clinic and grants from the National Cancer Institute (R01 CA138402, R01 CA138398, R01 CA163881 and P50 CA142509), the Leukemia and Lymphoma Society and Multiple Myeloma Research Foundation.
The authors declare no competing financial interests.
About this article
Cite this article
Lu, Y., Zhang, M., Wang, S. et al. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun 5, 4229 (2014). https://doi.org/10.1038/ncomms5229
This article is cited by
Cellular and Molecular Life Sciences (2023)
Cancer Immunology, Immunotherapy (2023)
Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma
Cancer Cell International (2022)
Journal of Hematology & Oncology (2020)
Germline genomes have a dominant-heritable contribution to cancer immune evasion and immunotherapy response
Quantitative Biology (2020)